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1.  ABSTRACT 
The prevalence of diabetes is increasing rapidly in Finland. The increase is mainly due to a 
sedentary lifestyle and obesity, but other unknown factors most certainly also play a role, 
especially in diabetes of children and young adults. Diabetes is a strong risk factor for 
macrovascular complications. Since the incidences of acute coronary syndrome (ACS), stroke 
and major amputations are decreasing in Finland, it is important that diabetic patients 
benefit from these favourable developments as well as does the general population. 
To study the development, we analysed the trends in case fatality (CF) of the first ACS and 
first ischaemic stroke, the incidence of lower-extremity amputations and population 
attributable-fractions (PAFs) of ACS and ischaemic stroke due to diabetes.  
 
We executed a register study combining information from the national reimbursement 
registers of medicines, Hospital Discharge Register and Causes-of-Death Register to identify 
all persons that have been treated with hypoglycaemic medication or registered with a 
diabetes diagnosis, and their macrovascular complications from 1992 to 2002. Comparisons 
were made in both genders and various age groups in the nondiabetic population. Data for 
comparison were available through the National Cardiovascular Disease Register. 
 
Our main findings were that the diabetic population has benefited from the favourable 
development to the same extent as the nondiabetic population (I, II). Prognoses after the 
first ACS and the first ischaemic stroke are improving. The incidence of lower-extremity 
amputation is decreasing (III). The prognoses of patients with diabetes are still, however, far 
from the prognoses of the nondiabetic population. Patients with type 2 diabetes (T2DM) had 
a total 1-year CF of 65.2% compared with 56.5% among nondiabetic men after their first ACS 
(I). The corresponding figures for women were 61.0% and 48.3%. The risk ratio (RR) for 28-
day CF after the first ACS was 1.34 (95% CI (confidence interval) 1.24–1.45) among T2DM 
men 35–64 years of age compared with nondiabetic men in the same age group, and 1.69 
(95% CI 1.44–1.97) among T2DM women with nondiabetic women, again in the same age 
group. The difference was greatest in the younger age groups and became less clear in the 
older age groups. The risk of fatal outcome within a year for 28-day survivors was 
considerable in patients with T2DM, RR 2.87 (95% CI 2.19–3.75) among men and 5.84 (3.70–
9.23) among women 35–64 years of age. There was a statistically significant downward trend 
in 28-day CF and in 1-year CF of 28-day survivors both among patients with T2DM and 
nondiabetic patients. The trends did not differ between patients with T2DM and nondiabetic 
persons.  
 
The total 1-year cardiovascular disease (CVD) CF after the first ischaemic stroke was 1.2–1.6 
times higher among patients with T2DM compared with nondiabetic persons, depending on 
gender and age group (II). The 28-day CF was 1.1–1.3 times higher among patients with 
T2DM. The difference was biggest in the younger age group of men. The 1-year CVD CF of 28-
day survivors was 1.4–2.2 times higher in patients with T2DM and this difference was biggest 
in the younger age group of women. There was a statistically significant downward trend 
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during the study period in CF of the first ischaemic stroke at 0–27 days and 28–364 days after 
the stroke. The trends did not differ between patients with T2DM and nondiabetic persons.  
 
The crude rate of first amputations decreased from 924 to 387 per 100 000 diabetic persons 
(III). The decrease was similar in men and women. There were major differences in the pace 
of development among the hospital districts. The ratio of minor and major amputations had 
a positive development during the study period and the rate of first major amputations 
among diabetic patients decreased in the Finnish population. 
 
The PAF of the first CVD event due to diabetes showed an upward trend among men from 
11.4% (95% CI 10.8–12.0%) to 13.8% (95% CI 13.2–14.5%), p for trend < 0.0001, and a 
downward trend among women from 20.1% (95% CI 19.2–21.0%) to 16.9% (95% CI 15.9–
17.8%), p for trend 0.0005 (IV). The upward trend was statistically significant in the first ACS 
event among men and the downward trend was statistically significant in the first ischaemic 
stroke in women. 
 
In conclusion, our results showed that the contribution of diabetes to the burden of first CVD 
events remained considerable. However, despite the increase in prevalence of diabetes, the 
PAF of the first CVD event decreased in women and increased only slightly in men.  
 
Strong actions should be taken to improve comprehensive treatment of risk factors after 
diagnosis of diabetes mellitus and efficiency of secondary prevention after a cardiovascular 
event. Special attention should be focused on better secondary prevention, because the 
largest difference between T2DM and nondiabetic persons was in 1-year prognosis of 28-day 
survivors after the first ACS or ischaemic stroke.  
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2.  INTRODUCTION 
The prevalence of diabetes mellitus (DM) is increasing rapidly in Finland. The increase from 
1997 to 2007 was 65%. In all 284 832 persons were treated with medicines for DM in 2007 
(1). Most of the increase concerns type 2 diabetes (T2DM), in which the increase was 77% 
during the same period. The yearly number of newly diagnosed diabetic patients is also 
increasing. The incidence of DM was 83% higher in 2007 than in 1997 (1). Some of the 
increase in the incidence of T2DM is explained by changes in diagnostic criteria and wide 
screening for early diagnosis, but the overweight, sedentary lifestyle and growing age of the 
population are also considered to explain the increase (2).  
 
DM is associated with enhanced development of macrovascular complications (3), such as 
myocardial infarction, stroke and peripheral vascular disease. Microvascular complications, 
such as renal insufficiency or retinopathy causing visual impairment, are more specific for 
DM (4,5). Complications of DM cause both human suffering and growing healthcare costs. 
Type 1 diabetic patients with complications have 6-fold healthcare costs compared with 
those without complications (6). In T2DM healthcare costs are 4.4-fold among those with 
complications (6).  
 
Cardiovascular (CV) events are decreasing in number and the prognosis after acute coronary 
syndrome (ACS) (7), stroke (8) and lower-extremity amputation (LEA) (9) has improved in 
Finland. It is not clear if persons with diabetes have benefited as much from the new and 
better treatments as nondiabetic persons. It is known that DM is a major health problem 
causing invalidity and early death (10). Good care of DM can prevent CV and other 
complications (11). All measures that help to improve treatment and prevent complications 
are of the utmost importance. This study presents information on the entire population of 
Finland over a long period of time. The development of complications reflects the quality of 
care and corrective actions should be considered if the outcome is not favourable. 
 
Our study population consisted of all persons in Finland that were treated with medicines for 
DM. It is a register-based study that comprises the national registers of reimbursement for 
hypoglycaemic medicines, the Hospital Discharge Register (HDR) and the Causes-of-Death 
Register. This study aimed to evaluate whether the population with DM has benefited from 
treatments as much as the nondiabetic population. To answer the question, the case fatality 
(CF) proportions of first ACSs and ischaemic strokes were calculated and trends in 28- and 
28–364-day CV CF were studied. The rates of LEAs were also studied as well as the 
population-attributable fraction (PAF) of ACS and ischaemic stroke due to DM. Even 
internationally there is very little current information on the PAF of cardiovascular diseases 
(CVDs) due to DM, although this information should be the basis for political decisions and 
setting of priorities. 
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3.  REVIEW OF THE LITERATURE 
3.1  Definition and types of diabetes mellitus 
DM is a metabolic disease in which the blood glucose levels are chronically elevated. It is 
considered to be a group of diseases with both differing genotypes and phenotypes. The 
blood glucose is elevated due to the lack of insulin, insulin resistance or poor effect of insulin. 
The World Health Organization (WHO) defined DM in 1999 as a metabolic disorder of 
multiple aetiology characterized by chronic hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin 
action or both (12). The manifestation of clinical DM is a result of both lifestyle and genetic 
factors. In most cases, DM has a multigenic background, but there are also monogenic forms 
of DM (13). 
 
The diagnosis of DM is based on plasma glucose level. The definition of DM has changed 
through the years. The current diagnostic criteria include: after fasting (at least 8 hours) 
plasma glucose ≥ 7.0 mmol/l; HbA1c (glycosylated haemoglobin) ≥ 6.5% (using the 
standardized Diabetes Control and Complications Trial (DCCT) assay); 2-hour plasma glucose 
≥ 11.1 mmol/l in the oral glucose tolerance test using a 75-g glucose load or random plasma 
glucose ≥ 11.1 mmol/l in a person with diabetic symptoms (14). The test should be repeated 
if the patient does not have the classical symptoms of DM. 
 
The main types of DM are type 1 diabetes (T1DM) and T2DM. In T1DM insulin production in 
the pancreas diminishes, due to an autoimmune process that destroys the insulin-producing 
beta-cells. The disease usually starts in childhood or the teenage years. Persons with T1DM 
require insulin for survival. A similar autoimmune process can also start later in life, often 
after the age of 35, resulting in insulin deficiency. This type of diabetes is called LADA (latent 
autoimmune diabetes in adults). It resembles T2DM in the slow development of the disease. 
T2DM usually starts in adulthood, with increasing incidence by age. In the LADA type of DM 
the insulin production diminishes more rapidly than in T2DM.  
 
T2DM is characterized by changes in insulin secretion and action. Resistance to insulin causes 
not only hyperglycaemia, but also other harmful metabolic changes. Patients are often 
overweight in T2DM (15). MODY (maturity-onset diabetes in the young) is a group of DM 
types caused by monogenic disturbances with insufficient insulin response to glucose (16). 
Typically, the disease is detected in adolescence or young adulthood. It does not have the 
same kind of destructive autoimmune process of the pancreas as T1DM. Another strongly 
hereditary DM type is mitochondrial DM with deafness (17).  
 
Temporary elevation of blood glucose can be seen in acute illnesses or stress. This is also the 
case with gestational DM during pregnancy (18). Sometimes even neonatal DM can 
disappear (19). 
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3.2  Pathogenesis and risk factors of diabetes 
 
In T1DM the autoimmune process destroys the beta-cells of the pancreas. This results in a 
total or nearly total deficit of insulin. The initiation of the disease is considered to be the 
result of environmental influence on genetically predisposed persons (20).  
 
In T2DM patients often have hyperinsulinaemia, insulin resistance and disturbed beta-cell 
functioning (21). The pathogenesis of T2DM is not known, but the lack of exercise, excessive 
energy intake and reduced energy consumption seem to play roles (2). In the U.S. (the United 
States of America) it was estimated that the lifetime DM risk at 18 years of age increased 
from 7.6% to 70.3% between underweight and very obese men (22). Among women the 
increase was from 12.2% to 74.4% (22). In addition, dysfunctional adipose tissue in obesity 
(23) and an impaired incretin system (24) have been claimed to play roles in causing T2DM. 
Since mitochondria are central to fuel consumption and energy production, it is also believed 
that mitochondrial dysfunction plays a role in the pathogenesis of T2DM (25). The risk for 
T2DM can be predicted fairly accurately by simple measurements and health habit 
information (26). 
 
T1DM has a strong genetic basis. Human leukocyte antigen (HLA) genes play a major role, but 
several non-HLA candidate genes have been detected as well (27). Some people have a 
genetic predisposition to acquire T2DM. The aetiology of T2DM is polygenic and the clinical 
expression often requires a sedentary lifestyle (28). The increasing number of predisposing 
risk genes increases the risk of disease. MODY-type DM is caused by a single gene defect and 
can therefore be determined by DNA (deoxyribonucleic acid) analysis (16). Neonatal DM is 
also caused by a single gene defect (19).  
 
3.3  Prevalence and incidence of diabetes  
 
The prevalence of DM has increased rapidly in Finland. The prevalence of persons treated 
with hypoglycaemic medication doubled from 1988 to 2002 (Fig. 1) (29). The rapid increase 
in prevalence has also continued after 2002. The number of diabetic patients increased by 
65% from 1997 to 2007 (1). A total of 284 832 persons were treated with hypoglycaemic 
medication in 2007. Most of the increase has been due to T2DM in which the increase in 
prevalence was 77% from 1997 to 2007 (1).  
 
The increasing prevalence of DM is a worldwide phenomenon (30,31). Its development in the 
U.S. has been similar to that in Finland (32). In China, the prevalence of DM was 10.6% in 
adult men and 8.8% in adult women in 2007 (33). The prevalence has increased together 
with the changes in population characteristics: increasing age, body mass index (BMI) and 
people living under urban conditions (33). The world prevalence of DM among adults (20–79 
years of age) was estimated to be 7.7% by the year 2030, including a 69% increase in the 
numbers of adults with DM in the developing countries and a 20% increase in the developed 
countries from 2010 to 2030 (31). 
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Figure 1. Prevalence of diabetes during 1988–2002 in Finland (29). 
 
 
 
The number of newly diagnosed diabetic patients has also increased constantly in Finland (1). 
The increase in incidence of DM concerns both T1DM and T2DM. The incidence of DM was 
83% higher in 2007 than in 1997 (1). This development resembles again the development 
reported from the U.S. (Fig. 2) (32). 
 
Some of the worldwide increase can be explained by the new definition of DM given in 1999, 
when the diagnostic plasma glucose level was lowered to 7.0 mmol/l from the previous 7.8 
mmol/l (12). The screening, diagnostic and treatment activities of DM have also increased 
(34,35) after the harmful effects of hyperglycaemia were shown convincingly (3,4). Studies 
from several countries have shown that many people are unaware of their DM (36–38). As 
late as in 2007, a population survey in Finland showed that two thirds of diabetic persons did 
not know about their illness (39).  
 
The reasons for the increase in incidence of T1DM are still unknown. Environmental factors 
and/or childhood diet are believed to play a major role (40). 
 
Gestational DM is a risk factor for the future development of T2DM (41). In a meta-analysis, 
women who had gestational DM had 7.43 (95% confidence interval (CI) 4.79-11.51) -fold risk 
for developing T2DM compared with those without gestational DM (41). The risk for a 
mother and also for her child of acquiring DM after gestational DM was predicted by the 
mother’s high BMI 15 years after the delivery (42).  
 
T2DM can be prevented or at least postponed with lifestyle interventions targeted to weight 
reduction by physical exercise and changes in eating habits (43). Increase in leisure time 
physical activity can prevent DM (44). Lifestyle interventions seem to have a long-lasting 
influence in preventing DM (45), with a delay in the onset of DM in high-risk adults (number 
needed to treat (NNT) 6.4) (46).  
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Figure 2. Incidence of newly diagnosed diabetes in the U.S. during 1980–2007 and projected 
future scenarios, including 95% confidence intervals (CI) (32) (Open access material, free for 
use). 
 
3.4  Complications of diabetes 
 
The vascular complications of DM are divided in micro- and macrovascular complications. 
Microvascular complications include nephropathy, neuropathy and retinopathy. 
Microvascular complications are strongly related to the level of hyperglycaemia (4,5). 
Macrovascular complications include coronary artery disease, cerebrovascular disease and 
peripheral arterial disease (PAD). The effect of blood glucose level on macrovascular 
complications is not clear in T2DM (47). 
DM also increases the risk of several other diseases, such as liver disease, infections, mental 
disorders, self-harm, chronic obstructive pulmonary disease and cancer (48–53). The risk of 
cancer death is increased in liver, colon and breast cancers in both genders (54). Among 
diabetic women, the risk of cancer death is increased in endometrium cancer and among 
diabetic men in oral cavity, pharynx and bladder cancers (54). 
In general, DM reduces the life expectancy of a 50-year-old person by about 6 years, and 
about 40% of the difference in survival compared with nondiabetic persons is due to excess 
in nonvascular deaths (53). A 1.80 (95% CI 1.71–1.90) hazard ratio (HR) was shown among 
persons with DM in comparison to those without DM for all-cause mortality and 2.32 (95% CI 
2.11–2.56) for CV mortality (53). In England and Wales the additional mortality among 
persons with DM was estimated to be 39.8% (10). 
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3.4.1  Complications in type 1 diabetes 
 
Patients with T1DM develop both micro- and macrovascular complications. After 30 years of 
conventional therapy (insulin once or twice per day), 50% had proliferative retinopathy, 25% 
had nephropathy and 14% CVD. In the intensive treatment group, the figures were 21%, 9% 
and 9%, respectively (55). Development of nephropathy doubles the risk for CV death (56).  
 
The DCCT, which tested the effect of intensive glucose treatment in patients with T1DM, 
showed a risk reduction in microvascular complications (5). The Epidemiology of Diabetes 
Interventions and Complications (EDIC) study, an observational follow-up of the DCCT study 
T1DM cohort, showed a decrease by 42% (95% CI 9–63%, p = 0.02) in the intensive glucose 
treatment group in CV complications (57). The intensive intervention also resulted in 63% 
reduction in retinopathy progression, 47% decrease in the development of severe 
nonproliferative diabetic retinopathy, 39% and 54% reductions in microalbuminuria and 
macroalbuminuria, respectively, and 60% reduction in clinical neuropathy at 5 years from the 
beginning of study (57). Aggressive early intervention before the manifestation of 
complications yielded the best results. In both the intensive and conventional treatment 
groups in the DCCT, there was approximately a 40% reduction in the risk of retinopathy 
progression for each 10% proportional reduction in HbA1c (58).  
 
The initial treatment of risk factors at the beginning of the disease plays an important role in 
the development of CV complications (59). An additional 10-year follow-up of DCCT patients 
after completion of the randomized trial showed a legacy effect that resulted in hazard 
reductions of 53–56% (p < 0.001) in the progress of diabetic retinopathy (60). The 
development of retinopathy was almost totally explained by reduction in the mean HbA1c 
level (61). The beneficial effect of intensive glucose treatment also proved to protect against 
hypertension and nephropathy 7–8 years after the initial trial (62). Prior intensive treatment 
was protective even for arterial calcification (HR 0.72 (95% CI 0.55–0.94)), but not for 
occlusion measured by the ankle-to-brachial ratio index (ABI) (63, 64).  
 
3.4.2  Complications in type 2 diabetes 
 
T2DM is associated with CV complications, such as coronary heart disease (CHD), stroke and 
limb ischaemia, but also with microvascular complications, such as nephropathy (65,66), 
neuropathy (67) and retinopathy (68). Liver dysfunction is one of the comorbidities in T2DM 
(69). In addition, obstructive sleep apnoea is also a comorbidity in T2DM (70). Hypertension 
is common among newly diagnosed T2DM patients. At 2 and 9 months after the diagnosis of 
DM, 35% of the males and 46% of the females were hypertensive (mean blood pressure (BP) 
≥ 160 mmHg systolic and/or ≥ 90 mmHg diastolic) (71). Patients with both hypertension and 
DM have approximately four times the CV risk of nondiabetic nonhypertensive subjects (72). 
 
T2DM increases the risk for CHD (73,74). It was estimated, based on the Framingham study, 
that after adjustment for age, sex and CHD risk factors, the risk of CHD was 1.38 times higher 
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for each 10-year increase in duration of DM (95% CI 0.99–1.92), and the risk for CHD death 
was 1.86 times higher (95% CI 1.17–2.93) for the same increase in duration of DM (75). The 
Euro Heart Survey suggested that actually the majority of patients with acute manifestations 
of coronary disease have either DM or abnormal glucose regulation (76). Stroke is also more 
common in persons with T2DM than in nondiabetic persons: 1.5–5 times more common in 
men and 2–8 times more common in women (77–79). Of about 600 T2DM patients 60 years 
of age or older in the Netherlands, 27.7% (95% CI 24.1–31.4%) had previously unknown heart 
failure (80). 
 
A cross-sectional study from Spain, in which a random sample of 2642 T2DM patients treated 
in primary care during 2007 was examined, showed a 34.1% prevalence of kidney disease 
measured by lowered glomerular filtration rate (66). In France, the prevalence of chronic 
kidney disease among 8926 T2DM patients, mean age 66 years, was 29% in 2007 (81). In 
India, a study of 1414 newly diagnosed T2DM patients revealed a 4.8% prevalence of diabetic 
retinopathy and 10.5% prevalence of both diabetic nephropathy and neuropathy (82). 
 
3.5  Macrovascular complications in diabetes 
3.5.1  Epidemiology, risk factors and prevention of macrovascular disease in 
persons with diabetes  
  
The risk of CVD in men with DM is 3-fold and in women with DM 5-fold in comparison to 
those without diabetes (11). DM accounts for 56% of all CVD events in men and 78% in 
women (3). Most CVD deaths occur in those with DM (3). Several risk factors contribute to 
the development of CVDs in DM, e.g. high blood glucose, dyslipidaemia, high BP, 
microalbuminuria, obesity, male gender and age. Active treatment of multiple risk factors in 
T2DM is apparently beneficial (83–85). Low socioeconomic status, depression, stress and 
anxiety increase CVD risk in all persons, including patients with DM (11). 
The ADDITION-Europe study, which was a cluster-randomized trial aiming at multiple risk 
factor reduction in 3057 screen-detected T2DM patients, was not able to show a significant 
decline in CV events within 5 years (86,87).  
BP treatment of patients with DM lowers the incidence of CV complications (88), and it is 
apparently less important which drug or combination of drugs is used (89). Sowers et al. 
estimated in their review article that 75% of CVD is explained by high BP in patients with DM 
(90).  
The United Kingdom Prospective Diabetes Study (UKPDS) showed that the higher a patient’s 
blood glucose level, the higher is the risk of dying of ACS or stroke in T2DM (91). A 
percentage point decrease in HbA1c decreased DM-related mortality by 21%, myocardial 
infarctions by 14% and microvascular complications by 37% (92). 
On the other hand, several other studies were unable to show reduction in CV complications 
after intensive glucose control in T2DM (93–96). The Action to Control Cardiovascular Risk in 
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Diabetes (ACCORD) study showed no benefit from intensive treatment compared with 
standard therapy. CVDs, a composite of CVD death, nonfatal myocardial infarction and 
nonfatal stroke, were not reduced with the intensive treatment strategies (97). However, the 
total mortality increased, when the treatment goal for HbA1c was < 6.0% compared with the 
standard therapy goal of 7.0–7.9% (95,98). The Outcome Reduction with an Initial Glargine 
Intervention (ORIGIN) trial was likewise unable to show any statistically significant 
differences in CVD event rates or CVD deaths among patients with disturbed glucose 
tolerance (99). A recent meta-analysis comprised of 13 randomized trials on intensive 
glucose control in T2DM suggested no significant changes in total mortality or CV mortality, 
but showed a reduction in nonfatal myocardial infarctions, risk ratio (RR) 0.85 (95% CI 0.74–
0.96, p < 0.001) (100). Another meta-analysis examining the benefit of intensive glucose 
control in T2DM showed a 17% reduction in nonfatal myocardial infarction events, odds ratio 
(OR) 0.83 (95% CI 0.75–0.93) and a 15% reduction in CHD events, OR 0.85 (95% CI 0.77–0.93) 
in the intensive care group, but no change in stroke events or all-cause mortality (101). The 
results were unexpected, because poor glycaemic control had in previous studies suggested 
an increase in CV events (91,92). Subgroup analyses of these large trials have provided 
evidence that patient characteristics, such as age, DM duration and tendency to 
hypoglycaemia are important (102). The differences between the results of the UKPDS study 
(91) and ACCORD (97), Action in Diabetes and Vascular Disease - PreterAx and DiamicroN MR 
Controlled Evaluation (ADVANCE) (94) and Veterans Administration Diabetes Trial (VADT) 
(93) study results have been explained by the fact that the UKPDS recruited newly diagnosed 
T2DM patients, while the other studies also included patients with a long DM history (103). 
The influence of duration of DM was shown in the VADT study, which targeted difficult-to-
control diabetic patients (104). 
A meta-analysis showed an overall RR of 1.26 (95% CI 1.16–1.36) for LEA for every 
percentage point increase in the HbA1c level (105). This meta-analysis did not distinguish 
T1DM from T2DM. 
Dyslipidaemia, e.g. elevated triglycerides, low levels of high-density lipoprotein cholesterol 
and high levels of low-density lipoprotein cholesterol (LDL-C), is a risk factor for 
macrovascular diabetic complications (106,107). Lowering LDL-C with diet or lipid-lowering 
medication has been an important aim in reducing the CV risk of patients with DM. Statins 
reduce all-cause mortality by 9% and major vascular events by 21% for every mmol/l -unit 
decrease in LDL-C (108). Data from the Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) study and ACCORD Lipid study suggest that fenofibrate reduces CV 
complications only slightly (109–111). 
 
Microalbuminuria strongly predicts CV morbidity and mortality in individuals with DM (112). 
In a cohort study, the risk for CHD or stroke was doubled in those with microalbuminuria in 
comparison to those without (113). 
 
Obesity increases the risk of CHD through insulin resistance, DM, arterial hypertension and 
dyslipidaemia (114). Insulin resistance and the compensatory hyperinsulinaemia are 
predictors of CHD (115). Insulin sensitivity improves with weight loss (116). Weight reduction 
improves lipid profiles and inflammation (117), which leads to a decrease in CV risk.  
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Bariatric surgery is used in obese T2DM patients to reduce CV risk factors and incidence of 
T2DM (118). It also reduced CV deaths in obese Swedish patients, HR 0.47 (95% CI 0.29–0.76) 
and first-time CV events, adjusted HR 0.67 (95% CI 0.54–0.83) (119). Bariatric surgery 
resulted in better glycaemic control than conventional therapy in severely obese T2DM 
patients (120). Apparently, even the occurrence of retinopathy decreases after bariatric 
surgery (121). This improvement could not be explained by improvement in glycaemic 
control only (121). The mechanism by which bariatric surgery promotes rapid improvement 
in systemic metabolism and long-term weight loss remains incompletely understood (122). A 
6-year follow-up comparing treatment of extremely obese patients with conventional 
therapy and bariatric surgery showed higher rates of DM remission and lower risk of CV 
events measured by changes in risk factors (123). The long-term effects of bariatric surgery in 
preventing CVD remain to be seen. 
 
Recent studies have examined the predictive roles of novel risk factors in development of 
CVD. The novel measures that have been studied include C-reactive protein, lipoprotein-
associated phospholipase A, genetic markers and markers of subclinical organ damage, for 
which there are varying levels of evidence (2, 124). There is some evidence that oxidative 
stress markers play a role in CVD development (125). Oxidized-LDL-C, myeloperoxidase, 
nitrotyrosine and lipid peroxidation measures are used as such markers. Biomarkers from 
genomics, transcriptomics, proteomics and metabolomics have also been examined (126). 
Mildly elevated serum bilirubin levels seem to have a protective effect against CVD and also 
DM (127).  
 
Genetic control influences CHD morbidity directly and also via control of the various risk 
factors (128,129). 
The above list of recent literature shows, more than 20 years after we began collecting our 
research data, that there are still controversies over the real benefit of treating different risk 
factors. During the study years and also before the appearance of diabetic complications, 
knowledge of the causes of these complications has affected the treatment regimens in 
many ways. 
 
3.5.2  Epidemiology, risk factors and prevention of acute coronary syndrome  
 
DM is a severe risk factor for CHD death, increasing the risk among men to 2–3-fold and 
among women to 3–6-fold (74, 130). The large, cross-sectional INTERHEART study in 52 
countries estimated that 9.9% of myocardial infarctions were due to DM (131). Hypertension 
triples the CHD risk among patients with T2DM (132). A study in Sweden showed that DM is 
the strongest risk factor for recurrent myocardial infarction (133). 
In Ontario, Canada the rate of patients admitted to hospital for acute myocardial infarction 
fell from 1992 to 2000 to a greater extent in the diabetic than in the nondiabetic population 
(-15.1% vs. -9.1%, p < 0.0001), but because at the same time the number of persons with DM 
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increased from 405 471 to 670 602, the number of coronary events among persons with DM 
increased by 44.6% and ACS deaths by 17.2% (134). 
The National Health and Nutrition Examination Survey (NHANES) I (from 1971 to 1975) and 
the Epidemiologic Follow-up Survey (from 1982 to 1984) followed the cohorts for 8–9 years 
and showed a 16.6% decrease in ischaemic heart disease mortality between the cohorts 
among men with DM, while the decrease was 43.8% for nondiabetic men. Women with DM 
showed a 10.7% increase during the same period, while nondiabetic women showed a 20.4% 
decrease in ischaemic heart disease mortality. The change was significant for nondiabetic 
men, but not for men with DM or women (135). 
Many reports have emphasized the disproportionately increased risk of coronary disease 
that DM brings about in women (136,137). The Framingham study showed that the presence 
of DM doubled the risk for recurrent infarction in women but not in men after the first ACS 
event (138). The RR in men was 1.6 (95% CI 1.0–2.4) and in women 2.5 (95% CI 0.9–6.9) 
(138). These findings were, however, challenged in a meta-analysis of 16 studies that 
adjusted for classic coronary risk factors (age, hypertension, total cholesterol and smoking) 
but which found no excess RR for CHD mortality, depending on gender (74). 
A cohort study examined the influence of alcohol intake in type 2 diabetic persons. Alcohol 
had a protective effect against CHD death at all the doses examined (139). The Nurses’ 
Health Study showed similar benefits, both in preventing fatal and nonfatal coronary disease 
(140). 
 
3.5.3  Effect of diabetes on case fatality of acute coronary syndrome 
 
The elevated risk of CHD death in individuals with DM can be due either to increased 
incidence of ACS events, or increased CF, or both. The WHO project Multinational Monitoring 
Trends and Determinants of Cardiovascular Disease (MONICA) highlighted the situation in 
several countries. The CF of the first ACS was compared in three countries from the late 
1980s to the mid-1990s (Table 1). In Australia the RR of fatal outcome at 28 days after the 
onset of first ACS among the 5322 patients in hospital care was 1.56 (95% CI 1.19–2.04) 
among women with DM and 1.25 (95% CI 1.02–1.53) among men with DM compared to their 
nondiabetic counterparts (141). 
 
A corresponding study in Finland that examined 4065 first ACS patients 25–64 years of age 
revealed an RR of 2.60 (95% CI 1.71–3.95) for death within 28 days among women with DM 
and 1.58 (95% CI 1.15–2.18) among men with DM (142). The RR of prehospital death was 
0.95 (95% CI 0.58–1.54) among women with DM and 1.25 (95% CI 1.03–1.52) among men 
with DM. The RR of 1-year fatality of 28-day survivors was 4.17 (95% CI 2.05–8.51) among 
women with DM and 1.97 (95% CI 1.25–3.12) among men with DM. In that study, the total 1-
year excess risk for death after the first ACS was 1.86 (95% CI 1.40–2.46) for women with DM 
and 1.38 (95% CI 1.18–1.61) for men with DM.  
 
16 
 
Table 1. Short- and long-term case fatality (CF) after the first acute coronary syndrome. 
Comparison of studies in three countries, (N = number of persons observed). 
Study and 
study years 
Country Persons 
with 
diabetes (N)  
(age range) 
Out-of-
hospital CF 
men/ 
women 
CF at days  
1–28 
men/ 
women 
CF at 1 year 
men/women 
Comment 
Chun B et 
al., 1985–
1994 (141) 
Australia 557  
(age 30–69 
years)  
Not 
available 
25%/  
25% 
Not available Hospitalized 
patients only, 
CF is age-
adjusted 
Miettinen H 
et al., 1988–
1992 (142) 
Finland 620  
(age 25– 64 
years) 
28.3%/ 
10.4% 
14.4%/ 
21.7% 
44.2%/36.9% 
(15.9%/25.9%, if 
excluding pre-
hospital deaths) 
1-year CF 
includes pre-
hospital 
deaths, 
CF is age- and 
area-adjusted 
Koek H et 
al., 1995 
(143) 
The 
Netherlands 
2018  
(all ages) 
Not 
available 
18%/ 
22% 
29.8%/26.9% Hospitalized 
patients only, 
CF is crude 
rate 
 
In the mid-1990s a nationwide register study in the Netherlands followed up persons with 
their first ACS (143). After multivariate adjustment, the 28-day RRs became nonsignificant. 
The RR for women with DM was 1.12 (95% CI 0.97–1.28) and for men with DM 1.16 (95% CI 
0.99–1.36). The corresponding 1-year multivariate-adjusted RR for women with DM was 1.33 
(95% CI 1.17–1.50) and 1.23 (95% CI 1.09–1.37) for men with DM. 
 
A population-based registry study from northern Sweden followed the time trends in ACS CF 
in the age group 35–64 years from 1989 to 2000 among both populations with and without 
DM (144). The 28-day CF decreased significantly in both nondiabetic men and women, but 
not in men and women with DM. The 1-year mortality rate also declined significantly among 
nondiabetic men and women but not among men and women with DM. However, there was 
a downward trend among women with DM in both 28-day and 1-year CF (144).  
 
A community-based study from Massachusetts in the U.S. examined the 1-year CF after an 
ACS among persons with diabetes during 1975–1999. The CF rates were higher for women 
than for men, 21.3% vs. 14.9%. The 1-year CF decreased from 39.2% to 17.5% among women 
with DM and from 18.9% to 9.5% among men with DM (145). 
 
3.5.4  Epidemiology, risk factors and prevention of ischaemic stroke 
 
The overall incidence of stroke has decreased in Finland, while the prognosis after stroke has 
improved during the period 1991–2002 (8). The age-standardized incidence of first-ever 
stroke decreased annually by 2.2% (95% CI 1.9–2.4%) among men and 2.5% (95% CI 2.2–
2.8%) among women 35–74 years of age. In patients 75–84 years of age, the decrease was 
2.6% per year (95% CI 2.2–3.0%) among men and 3.2% per year (95% CI 2.9–3.5%) among 
women (8). In the age group 35–74 years, the 28-day CF of first-ever stroke decreased 
annually by 3.2% (95% CI 2.5–3.9%) among men and by 3.0% (95% CI 2.2–3.8%) among 
women (8). A study in Sweden showed that the age-standardized overall incidence of first-
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ever stroke in the age group 35–65 years increased from 1989–1991 to 1998–2000 by 19% in 
men and 33% in women (146). Part of the increase may have been due to improved 
diagnostics and detection of smaller strokes. Furthermore, the study was based on the 
Hospital Discharge Register only and missed out-of-hospital stroke deaths, because no CVD 
register was in use. The out-of-hospital stroke deaths may have decreased during the study 
period. 
 
Stroke risk is increased 1.5–5-fold among men and 2–8-fold among women with DM (77–
79,147). The cross-sectional INTERSTROKE Study in 22 countries estimated that 5.0% of 
ischaemic strokes were caused by DM (148). Concomitant hypertension doubles the risk for 
stroke (132). In the U.S., a study investigated all admissions from Veterans Administration 
hospitals between 1990 and 1997 (N (number of persons observed) = 48 733) and showed 
that an increasing proportion of ischaemic stroke patients had DM, 31% in 1997 (149). In 
Canada, the rate of patients admitted to hospital for stroke fell to a greater extent in the 
population with DM than the population without DM, -24.2% vs. -19.4% (p < 0.0001) from 
1992 to 2000, but due to the increase in the number of persons with DM in the population, 
the stroke events increased by 26.1% and stroke deaths by 13.2% (134). 
 
A population-based study in Finland investigated patient prognosis after the first stroke 
event from 1990 to 1998 (150). The study showed, using logistic regression analysis, that DM 
is a predictor of disability after stroke, OR 1.51 (95% CI 1.27–1.81).  
 
3.5.5  Effect of diabetes on case fatality of stroke 
 
A study in Finland showed that the 28-day CF was higher in patients with DM than in those 
without (20.0% vs. 16.9%, p = 0.020) in the 1990s (150). A Veterans Administration hospital 
study between 1990 and 1997 showed no significant difference in 60-day or 1-year 
postdischarge mortality between the stroke patients with or without DM, but the Kaplan-
Meier survival plot showed that persons with DM had shorter long-term survival (log-rank, p 
< 0.001) and the multivariate Cox proportional hazards regression showed that the hazard of 
death for patients with DM was 15% more than for nondiabetic persons after controlling for 
other covariates (HR = 1.15, p < 0.001) (149).  
 
The National Acute Stroke Israeli Survey followed the first-ever acute ischaemic stroke 
survivors (N = 1079) starting in 2004 for 1 month and for 3 years. DM increased the HR of 
mortality to 1.6 (95% CI 1.0–2.4) among the 1-month survivors (151).  
 
A population-based register study in Sweden followed 15 382 stroke patients 35–74 years of 
age from 1985 to 2003. The CF and mortality of stroke declined for all groups, except women 
with DM after the first-ever stroke during the study period. The time trends in CF and 
mortality did not differ significantly between patients with and without DM (79). 
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Among 12 686 patients with an acute ischaemic stroke in Canada, those with DM had a less 
favourable outcome after thrombolysis than their nondiabetic counterparts, 24.3% vs. 
31.1%, RR 0.90 (95% CI 0.82–0.98) (152). 
 
3.5.6  Epidemiology, risk factors and prevention of lower-extremity 
amputation 
 
The global variation in the incidence of all forms of LEA ranges from 46.1 to 9600 per 100 000 
and of major (at or proximal to the ankle joint) amputation from 5.6 to 600 per 100 000 in 
the population with DM (153). The risk for LEA was over 20 times higher among patients with 
DM than in nondiabetic patients in the entire population of England (154). The risk for LEA 
was 8-fold among men and 6-fold among women with DM compared with nondiabetic 
persons in Germany (155). In Finland, a 7-fold risk was shown for a major amputation among 
persons with DM compared with nondiabetic persons (156). 
 
A study in England found no significant change in 1-year mortality after an amputation 
among diabetic persons from 2000 to 2004 (157). The study also showed a reduction in 
amputations among T1DM patients, but an increase among T2DM patients of from 2.0 to 2.7 
per population of 100 000 (157). A similar trend was shown from the Spanish HDR during 
2001–2008. In patients with T1DM, the incidence of minor (distal to the ankle joint) and 
major LEAs decreased significantly, from 0.88 to 0.43 per 100 000 inhabitants and from 0.59 
to 0.22 per 100 000 inhabitants, respectively. In patients with T2DM, the incidence of minor 
LEAs increased significantly, from 9.23 to 10.9 per 100 000 inhabitants and major LEAs from 
7.12 to 7.47 per 100 000 inhabitants, also significantly (158).  
 
A nationwide follow-up of T1DM patients, who had been identified from the HDR in Sweden, 
demonstrated a cumulative probability of nontraumatic LEA of 11.0% for women and 20.7% 
for men (p log-rank < 0.01) by the age of 65 years. The RR for nontraumatic LEA was 0.6 (95% 
CI 0.5–0.8) during 2000–2004, compared with the period 1975–1999 (159). 
 
The incidence of major amputations among persons with DM fell from 27.2 to 6.9 per 100 
000 inhabitants in Copenhagen, Denmark in a hospital-based study from 1981 to 1995 (160). 
Similar development was reported from the hospital in Lund, Sweden (161). The incidence of 
major amputations decreased from 16 (95% CI 11–22) to 6.8 (95% CI 6.1–7.5) per 100 000 
inhabitants between the first and last 4-year period from 1982 to 2001 (161). Ipswich 
Hospital in the U.K. reported a decrease in major amputations from 7.4 to 2.8 per 100 000 in 
the general population from 1995 to 2005 (162). 
 
Smoking is a strong risk factor for PAD, but hypertension, hypercholesterolaemia and T2DM 
are also associated with increased risk of PAD (163).  
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3.5.7  Total cardiovascular burden in diabetic individuals 
 
The Emerging Risk Factors Collaboration analysed data on over 820 900 people and found an 
HR of 2.32 (95% CI 2.11–2.56) for death from vascular causes among participants with DM, in 
comparison to those without DM, after adjustment for baseline age, sex, smoking status and 
BMI (53). DM exhibits approximately a 2-fold risk for most vascular complications (164). 
 
The population-based health surveys NHANES I, II and III compared CV mortality among 35–
74-year-old persons with and without DM in three cohorts which were started in 1971–1975, 
1976–1980 and 1988–1994. The mortality rates were determined through 1986, 1992 and 
2000 for the three surveys, respectively. The study demonstrated a decrease in CV mortality 
among men and women without DM. The changes were significant. There was also a 
decrease in CV mortality among men with DM, but this was not statistically significant. 
Among women with DM there was no change in CVD mortality (165). CVD has been the most 
common underlying cause of death in DM, accounting for 44% of deaths in T1DM and 52% of 
deaths in T2DM (166). 
 
A study in England concluded that there was a 5-fold risk among persons with DM for ACS 
admission to hospital and a 3.5-fold risk for stroke compared with nondiabetic persons (167). 
The study compared vascular admission rates in 2004 and 2009. ACS decreased, with a rate 
ratio of 0.95 (95% CI 0.93–0.97) per year among persons with DM. The development did not 
differ between genders in ACS, but it did in stroke, where men with DM had a rate ratio of 
1.00 per year (95% CI 0.99–1.01), but women showed a significant downward trend, rate 
ratio 0.99 per year (95% CI 0.97–0.99) (167). 
 
3.5.8  Population-attributable fraction of cardiovascular diseases due to 
diabetes 
 
The Framingham Heart Study estimated that the PAF of CVD due to DM increased from 5.4% 
(95% CI 3.8–6.9%) in the period from 1952 to 1974 to 8.7% (95% CI 5.9–11.4%) in the period 
1975–1998 (168). Based on data from the NHANES II study (1976–1980), the authors 
estimated that DM accounts for at least 3.6% of all deaths and 5.2% of CVD deaths in U.S. 
adults (169). 
 
In Malmö, Sweden a population screened from 1974 to 1992 was followed up for a 
maximum of 28 years. The population-attributable risk (PAR) of coronary events due to DM 
was estimated to be 3%, 6% for women and 2% for men (170). In Spain, the PAR of CHD due 
to DM was estimated to be 10.1% (95% CI 0–16.8%) (171). The latter study was based on a 
cohort of 6124 adults. 
 
In Japan, the PAF of CHD due to DM was estimated to be 6.3% between 1990 and 2006 (172). 
In Taiwan, the PAF of total mortality due to DM was 26.8% (95% CI 8.3–48.5%) among men 
and 19.9% (95% CI 3.4–42.3%) among women (173). 
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A study in Germany, covering a population of 1.6 million people in a statutory health 
insurance scheme, showed a PAF for the first nontraumatic LEA of 0.59 for men and 0.40 for 
women due to DM during the years 2005–2007 (155). The authors expected that the St. 
Vincent target of 50% reduction in amputations among persons with DM could be reached in 
Germany, because a previous study had shown a PAF of 0.72, due to DM (174).  
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4.  AIMS OF THE STUDY 
 
The main aim of the study was to examine the epidemiology of macrovascular complications 
of DM in the nationwide diabetic population in Finland during the period 1992–2002. The 
specific aims were to examine secular trends in 
 
1) the CF of the first ACS among all persons treated for T2DM in Finland, 
2) the CF of the first acute ischaemic stroke among all persons treated for T2DM in Finland, 
3) major LEAs, and the differences between the hospital districts in the incidence of major 
LEAs among the Finnish population with DM and 
4) the PAF of the first ACS and ischaemic stroke in Finland. 
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5.  MATERIAL AND METHODS 
5.1  Study population 
The study population comprised all persons in Finland who were treated with hypoglycaemic 
medicines for their diabetes (DM) during the period from 1988 to 2002. We also included 
patients for whom DM was listed among the diagnoses in the National HDR, irrespective of 
drug treatment. In all, 308 447 diabetic patients were included in the study. The setup of the 
study population is shown in Figure 3 (29). 
 
Figure 3. Setup of the study population, modified with author’s permission, originally 
published in Diabetes in Finland. Prevalence and Variation in Quality of Care (29) (THL – the 
National Institute for Health and Welfare, N = number of persons observed). 
 
 
  
5.2  Source registers and registry linkage 
 
The data for this study originated from four nationwide healthcare registers: two drug 
reimbursement registers of the National Social Insurance Institute, the National HDR of the 
National Research and Development Centre for Welfare and Health (Stakes), which currently 
is part of THL – the National Institute for Health and Welfare, and the National Causes-of-
Death Register of Statistics Finland. The special reimbursement (or special refund 
entitlement) register of medicines includes all patients with DM in Finland who have been 
entitled to special reimbursement for hypoglycaemic medication during the study period. 
These data extend back to 1964. To receive this special reimbursement the patient needs to 
obtain from his/her physician a statement documenting the clinical and laboratory findings 
23 
 
that have led to the diagnosis of DM. The statement is reviewed by an expert physician of the 
Social Insurance Institute before the special reimbursement is granted. In DM the 
reimbursement was 100% for hypoglycaemic medicines during the study period, which is 
why in practice every medically treated person with DM was included in the register. The 
Social Insurance Institute also keeps another register that has information on patients with 
DM. Since 1994 there has been a prescription register on persons who received 
reimbursement to standard amount (about half the price during the study period). The latter 
register also has information on those diabetic patients that did not receive the special 
reimbursement.  
 
The National HDR includes information on all hospitalizations in Finland. The diagnoses are 
recorded by the physician in charge of hospital care, using the International Classification of 
Diseases (ICD) codes. The ICD-10 classification has been used since early 1996 and the ICD-9 
classification previous to that. This study has information on diabetic persons and their 
complications obtainable from the HDR since 1988. The National Causes-of-Death Register 
information of the study population was also included since 1988. The Causes-of-Death 
Register has information on all deaths of Finnish citizens and permanent residents. The 
physician in charge of treatment codes the underlying and direct cause of death, using the 
ICD codes. The coding is then checked and revised if necessary, by a nosologist working 
under the guidance of a specialist in forensic medicine in Statistics Finland. The CV diagnoses 
in the Finnish HDR and in the Causes-of-Death Register have been validated (175–177).  
 
The registers listed above were linked together on an individual basis, using the personal 
identification code (ID) unique to every permanent resident in Finland. The personal ID 
includes a control part that minimizes the risk of mixing different persons in the registers. 
Pajunen et al. reported that “The number of erroneous personal IDs in the Finnish 
administrative registers is negligible and the quality of the HDR data has continually 
improved. In 1991, 0.26% of the personal identification codes in the HDR were incomplete; in 
2002, less than 0.08% of codes had any defects. None of the personal identification codes in 
the Causes-of-Death Register were incomplete.” (175).  
 
After the record linkage was performed, the personal ID was replaced with an artificial study 
ID to create an anonymous dataset for analyses. The Ethical Committee of the National 
Public Health Institute approved the study. 
 
5.3  Definitions of variables in the registers 
5.3.1  Diabetes mellitus 
 
DM was defined in the reimbursement registers by the use of hypoglycaemic medication 
with the ATC (the Anatomic Therapeutic Chemical classification system) code A10, and in the 
National HDR and in the Causes-of-Death Register with the ICD-9 codes 250 and ICD-10 codes 
E10–E14. 
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The type of DM was determined, based on the age at the time of first diagnosis and the type 
of treatment given. Patients who were under 30 years of age and treated with insulin only or 
in combination with metformin, as well as those who were between 30 and 40 years of age 
when treatment with insulin only was started, were considered to have T1DM. Those 
patients with DM who were under 30 years of age and in chronic institutional care were also 
considered to have T1DM if there was no knowledge of the type of medical treatment. All 
others were considered to have T2DM. 
 
5.3.2  Indicators of complications in diabetes 
 
The complications of DM were identified from the HDR and Causes-of-Death Register, using 
the ICD-9 and ICD-10 codes. All symptomatic complications that were considered in this 
study (ACS, ischaemic stroke and LEA) are treated in hospital in Finland. No attempt was 
made to identify clinically silent coronary or stroke events.  
 
Nonfatal ACSs, including myocardial infarction and unstable angina pectoris, were identified 
with the ICD-9 codes 410 and 4110 and the ICD-10 codes I20.0, I21 and I22 in the HDR. The 
fatal cases were identified with the ICD-9 codes 410–414 and 798 and the ICD-10 codes I20–
I25, I46, R96 and R98 in the Causes-of-Death Register. The vague codes 798, I46, R96 and R98 
are seldom used in Finland and hardly ever without an autopsy. They were included, 
however, for the sake of completeness, because the majority of these cases are of coronary 
origin. 
 
Ischaemic strokes were identified with the ICD-9 codes 433–434 and 436 (excluding codes 
4330X, 4331X, 4349X) and the ICD-10 codes I63–I64 (excluding code I63.6). The FINSTROKE 
study has shown that towards the mid-1990s, neuroimaging and/or autopsy have been 
performed on practically all patients with a symptomatic stroke (178).This has enabled a 
reliable distinction between the haemorrhagic and ischaemic stroke types, as also shown by 
validation studies (176). 
 
CV deaths were identified from the Causes-of-Death Register with the ICD-9 codes 410–414, 
798, 430–434, 436 and 438 and the ICD-10 codes I20–I25, I46, R96, R98, I60–I66 and I69 
(except for code I63.6) when used as the underlying or direct cause of death. Of the 
contributing causes of death, we included the ICD-9 codes 410 and 430–434 (except for the 
codes 4330X, 4331X, 4339X and 4349X) and the ICD-10 codes I21–22 and I60–64 (except for 
the code I63.6). 
 
LEAs were identified from the HDR by the surgical codes of the Nordic Medico-Statistical 
Committee (NOMESCO). Minor amputations were identified by the surgical codes NHQ30 
and NHQ40 and major amputations by the codes NGQ10, NGQ20, NHQ10 and NHQ20.  
 
In the ACS and ischaemic stroke studies, we focused specifically on the first event. In ACS and 
ischaemic stroke, it was defined as a 4-year incident-free period before the event. We 
estimated from our material that this 4-year period left us with about 8% falsely diagnosed 
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`first´ ACS events and about 11–12% falsely diagnosed `first´ ischaemic stroke events. The 4-
year rule was chosen because it resulted in fair accuracy, considering our study length. All 
patients who had an ACS, ischaemic stroke or transient ischaemic attack (TIA) before DM 
diagnosis were excluded from the material. 
 
In the ACS and ischaemic stroke studies comparison of the CF was made with the nondiabetic 
population. The comparison data came from the National Cardiovascular Disease Register 
(CVDR), which is based on record linkage of the HDR and the Causes-of-Death Register. The 
CVDR covers all ACS and ischaemic stroke events in Finland that have led to hospitalization or 
death. The register has been described in detail (179,180). The same ICD codes and the same 
definition for the first ACS events were used in this comparison material as in the diabetic 
material. Since we had no personal ID available in our DM register, we used probability-
based linkage of our DM register and the National CVDR to identify and remove diabetic 
persons from the National CVDR. For 45 persons (0.1% of patients with DM) in the ACS study 
and for 41 persons (0.2% of patients with DM) in the ischaemic stroke study, the linkage 
failed and these persons were excluded from the study population. The numbers of the 
population with DM and comparison population for each study year are presented in Table 2. 
 
Table 2. Number of all persons with diabetes, persons with type 2 diabetes (T2DM) and 
nondiabetic population (comparison population) in the age group of 35–94 years at the end 
of each year during 1988–2002 in Finland. 
Year Population with diabetes Population with T2DM Nondiabetic population 
 Number % women 
Average 
age 
(years) 
Number % women 
Average 
age 
(years) 
Number % women 
Average 
age 
(years) 
1988 76 620 58.9 65.7 68 714 61.1 68.2 2 479 294 53.8 54.3 
1989 85 135 58.3 66.3 76 617 60.4 68.7 2 505 789 53.7 54.4 
1990 95 790 57.7 66.8 86 598 59.6 69.1 2 529 477 53.6 54.4 
1991 100 481 56.6 66.6 90 583 58.5 68.9 2 561 843 53.5 54.4 
1992 104 709 55.6 66.5 94 102 57.5 68.8 2 590 106 53.5 54.5 
1993 108 971 54.8 66.4 97 698 56.6 68.7 2 613 158 53.4 54.6 
1994 111 511 54.0 66.5 99 546 55.8 68.9 2 641 716 53.3 54.7 
1995 113 894 53.4 66.5 101 390 55.1 67.0 2 669 284 53.3 54.8 
1996 117 920 52.7 66.4 104 938 54.2 68.9 2 695 000 53.2 54.9 
1997 123 142 52.0 66.4 109 695 53.4 68.8 2 719 912 53.1 55.0 
1998 128 213 51.4 66.4 114 237 52.7 68.7 2 745 653 53.1 55.1 
1999 134 061 50.8 66.3 119 532 51.9 68.6 2 768 647 53.1 55.2 
2000 142 698 50.1 66.2 127 623 51.1 68.4 2 786 526 53.0 55.4 
2001 152 573 49.5 66.1 136 937 50.3 68.2 2 804 953 53.0 55.5 
2002 165 288 49.0 66.0 149 077 49.6 68.0 2 818 528 52.9 55.7 
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5.4  Statistical methods 
5.4.1  Case fatality 
 
The prehospital, 28-day and total 1-year CFs of the first ACS were counted, as well as the 28-
day and total 1-year CFs for the first ischaemic stroke among patients with T2DM. 
Comparisons were made with persons without DM, using data from the National CVDR. Age-
standardization was made, using weights derived from the age distribution of myocardial 
infarction and stroke patients in the myocardial infarction and stroke registers of the WHO 
MONICA Project (181,182). 
 
The trends in prehospital coronary deaths were analysed using logistic regression and ORs 
(per1-year increment in time). HRs for 0–27-day and 28–364-day CV deaths after the first 
ACS and the first ischaemic stroke were computed separately for men and women with 
T2DM in four different age groups (35–64, 65–74, 75–84 and 85–94 years), and again 
comparing the results with the nondiabetic population. The variables of main interest were 
the study year, DM status (nondiabetic vs. T2DM) and the study year by DM status 
interaction, which was used to evaluate whether the CF trends differed between nondiabetic 
persons and persons with T2DM. The models were adjusted for age in 5-year age groups and 
for the university hospital district. In analysing trends in total 28-day CV CF and 28–364-day 
CF, we took the survival times into account, using Cox proportional hazards regression and 
HRs. The time scale for Cox models in the 28-day CF started from the date of hospitalization. 
The statistical analyses were carried out, using SAS software version 9.1.3 (SAS Institute Inc., 
Cary, NC, USA). 
 
5.4.2  Incidence rates 
 
The rates of first amputations were counted for each year from 1988 to 2002 both for men 
and women. The age- and sex-standardized incidence rates of first amputations were 
expressed per 100 000 persons with DM, while for regional comparison the data covering the 
20 hospital districts were clustered in 3-year periods to stabilize variation in small hospital 
districts. The incidence of lower extremity-vascular surgery was compared with amputation 
rate in 14 hospital districts with the highest prevalence of DM. 
 
The incidence rates of the first ACS and ischaemic stroke among patients with T2DM were 
counted separately for men and women in two age groups: 35–74 years and 75–94 years. For 
comparison, the rates were also counted for nondiabetic persons, using data from the 
National CVDR. The rates were age-standardized, using the European standard population as 
a standard (183). 
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5.4.3  Population-attributable fraction  
 
The number of patients with DM and the numbers of first ACS and ischaemic stroke events 
and PAF due to DM were calculated for each year separately for men and women from 1992 
to 2002. All patients in the age range 25–80 years for each year were included in the study. 
All calculations were made by full calendar years; if DM was diagnosed after the CVD event 
during the same calendar year, the event was considered to be a diabetic event. Annual 
population counts were obtained from the National Population Information System 
(http://pxweb2.stat.fi/database/StatFin/vrm/vaerak/vaerak_fi.asp). The PAF due to DM was 
also counted by combining the figures for both CV events, i.e. either the first ACS or the first 
ischaemic stroke for a patient with DM.  
 
The annual PAF with 95% CIs of first ACS and first ischaemic stroke due to DM were 
calculated according to the formula PAF = [[Pe*(RR–1)/{1+[Pe*(RR–1)]}]]*100, where RR is 
the risk ratio and Pe is the estimate of population exposure (184). The use of the formula is 
demonstrated in Example 1. The trends for PAF were estimated, using log-linear regression 
models with the year as an independent variable. We also calculated whether PAF differed 
by age group (25–54, 55–64 and 65–80 years) in both sexes.  
 
Example 1. Demonstrating the use of the PAF formula. 
 
 
 
 
 
 
When the RR for the first nontraumatic LEA is 6.0 in persons with DM compared with 
nondiabetic persons and 8% of the population present with DM, the PAF of the first 
nontraumatic LEA is [[0.08*(6–1)/{1+[0.08*(6–1)]}]]*100 = 28.6%. 
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6.  RESULTS 
6.1  Case fatality of acute coronary syndromes (I) 
 
Among the 222 940 patients 35–94 years of age with T2DM, 18 076 men and 21 295 women 
had their first ACS between the years 1992 and 2001. Patients with T2DM died of CV causes 
more often than nondiabetic patients. The 1-year fatality proportion in this age group was 
among men with T2DM 65.2% (95% CI 65.0–65.5%), when it was 56.5% (95% CI 56.4–56.6%) 
among nondiabetic men. The corresponding figures for women were 61.0% (95% CI 60.4–
61.5%) and 48.3% (95% CI 48.2–48.5%). 
 
The fatality proportion analyses showed similar differences, when separate analyses were 
made in the age groups 35–74 years and 75–94 years. The biggest difference was among 
women 35–74 years of age, in whom the 1-year fatality proportion difference was 17.3 
percentage points higher in women with T2DM (Table 3, reformulated from Table 1 in I).  
 
Table 3. All persons treated for type 2 diabetes mellitus (T2DM) in the age group 35–74 years 
in Finland, their first acute coronary syndrome (ACS) between January 1, 1992 and November 
30, 2002, and numbers and proportions with fatal outcome compared with the same 
information on nondiabetic patients identified from the National Cardiovascular Disease 
Register for the period 1992–2002. 
 
  Patients with T2DM Nondiabetic patients 
  Men Women Men Women 
Population Number 92 371 85 601 1 135 862 1 211 343 
First ACS Number 12 358 7038 70 714 26 106 
ACS with 
fatal 
outcome 
Prehospital 
Number 
Fatality 
proportion 
(%)  (95% CI) 
3274 
 
27.1           
(27.0–27.2) 
1229 
 
18.7          
(18.5–18.8) 
20 877 
 
29.7          
(29.7–29.8) 
5216 
 
19.8          
(19.7–19.8) 
ACS with 
fatal 
outcome 
Total 28-day 
Number 
Fatality 
proportion 
(%)   (95% CI) 
6269 
 
50.3          
(50.2–50.5) 
3131 
 
42.1       
(41.9–42.2) 
28 336 
 
41.0       
(41.0–41.1) 
8300 
 
30.1       
(30.0–30.1) 
ACS with 
fatal 
outcome 
Total 1-year 
Number 
Fatality 
proportion 
(%)   (95% CI) 
6563 
 
56.5          
(56.4–56.6) 
3544 
 
50.3 
(50.2–50.5) 
28 864 
 
44.5          
(44.4–44.5) 
8825 
 
33.0          
(32.9–33.0) 
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The total 28-day and 1-year fatality proportions were significantly higher statistically in both 
age groups and among both genders in the diabetic group, but the prehospital CF was 
significantly lower among patients with T2DM in both genders and age groups (Table 1 in I). 
Figure 4 shows the cumulative CF during the prehospital, 28-day and 1-year periods following 
the first ACS event. The figure is based on further analysis of data in I. 
 
Figure 4. Cumulative case fatality after the first acute coronary syndrome among men and 
women with type 2 diabetes (T2DM) and without diabetes (non-DM) in Finland during the 
years 1992–2002. 
  
 
 
The prehospital CF was higher among men than women, but the difference disappeared after 
the age of 85. This change occurred both in persons with T2DM and those without DM (Table 
2 in I).  
 
Downward trends in prehospital CF were seen during the study period in both genders and in 
all four age groups, both among patients with T2DM and without DM with their first ACS (Fig. 
1 in I). Testing the OR of DM by study year interactions showed that the trends in T2DM did 
not differ from those in nondiabetic patients, except for women 85–94 years of age, in whom 
the data suggested a steeper decline in women with T2DM. In the age group 35–64 years the 
OR for T2DM was nonsignificantly higher than 1.0, but after the age of 65 it was significantly 
less than 1.0 and became smaller in the older age groups.  
 
The total 28-day CV CF of ACS was significantly higher among T2DM patients in all age groups 
studied, except the oldest group of persons in the age group 84–95 years (Fig. 2 in I). In the 
age group 35–64 years, T2DM was associated with 34% higher 28-day CF in men and 69% 
higher CF in women. The 28-day CF of ACS decreased significantly, both in patients with 
T2DM and in nondiabetic patients in both sexes and in all age groups. The downward trends 
did not differ between patients with T2DM and nondiabetic patients. 
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Among the 28-day survivors, the age-standardized 1-year CV CF decreased significantly both 
among persons with T2DM and among nondiabetic patients with their first ACS (Fig. 3 in I). 
The trends did not differ between T2DM and nondiabetic patients. The RR remained 
considerably higher in patients with T2DM, especially in the youngest age group of 35–64 
years. The RR for men was 2.87 (95% CI 2.19–3.75) and for women 5.84 (95% CI 3.70–9.23). 
 
6.2  Case fatality of ischaemic strokes (II) 
 
Among the 222 940 patients 35–94 years of age with T2DM, 9593 first ischaemic strokes 
among men and 13 504 among women were observed during the years 1992–2002 (Fig. 5). 
The figure is based on further analysis of data in II. During the study years, 1.4–2.4% of 
patients with T2DM had their first ischaemic stroke each year. More than a third of them 
died from CV causes within a year after the stroke. Women had higher CFs of the first 
ischaemic stroke than men.  
 
Figure 5. Cumulative case fatality after the first ischaemic stroke among men and women 
with type 2 diabetes (T2DM) and without diabetes (non-DM) in Finland during the years 
1992–2002. 
 
 
 
Both the 28-day and 1-year CV CFs of stroke were higher among persons with T2DM in both 
sexes than in the nondiabetic population (Table 2 in II). The 28-day CF of ischaemic stroke 
was 1.1–1.3 times higher among T2DM patients than in nondiabetic patients, depending on 
gender and age group. The 1-year CF of ischaemic stroke of the 28-day survivors was 1.4–2.2 
times higher in patients with T2DM than in nondiabetic persons. The difference was smallest 
in the younger age group of men (35–75 years) and biggest in the younger age group of 
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women. The total 1-year CV CF of stroke was 1.2–1.6 times higher among patients with 
T2DM than in nondiabetic persons.  
 
There was a clear downward trend in the CV CF during days 0–27 and 28–364 of the 28-day 
survivors after the first ischaemic stroke both in persons with T2DM and nondiabetic persons 
(Figs. 2 and 3 in II). The trends were statistically significant in the age groups 35–74 years and 
75–94 years and in both genders, but no difference in trends was seen between patients 
with T2DM and nondiabetic patients.  
 
6.3  Lower-extremity amputations (III) 
 
Among the 308 447 diabetic persons, there were 11 070 patients who had an LEA and 9530 
persons with DM who had a vascular operation (endovascular procedures were not included) 
during 1988–2002. The crude rate of first amputations decreased from 924 to 387 per 100 
000 persons with DM (Fig. 2 in III). The decrease was similar in men and women. We found 
major differences in the pace of development between hospital districts. The ratio of minor 
and major amputations showed a positive development during the study period (Table 2 in 
III). The rate of first diabetic major amputations decreased rapidly in the Finnish population 
(Fig. 6). The figure is based on further analysis of data in III. 
 
Figure 6. Rates of first diabetic major amputations during the years 1988–2002 in Finland. 
 
  
 
The age- and gender-adjusted indexed incidence of first amputations varied up to 3-fold 
between different hospital districts during 2000–2002 (Table 1 in III). The study showed a 
clear inverse association between the incidence of first major amputations and first vascular 
operation (r = -0.771, p < 0.001). The association was even stronger in comparing the 
infrapopliteal reconstructions (r = -0.793, p < 0.0001). 
32 
 
6.4  Population-attributable fraction of acute coronary syndrome (IV) 
 
The number of men treated for DM increased from 37 073 to 69 158 between 1992 and 
2002. Among women, the increase was from 42 485 to 57 372. Despite this rapid increase in 
the number of persons treated for DM, the annual numbers of first ACS events among 
persons with DM increased only slowly among men and decreased among women (Fig. 7). 
The figure is based on further analysis of data in IV. The PAF of the first ACS, due to DM, 
increased among men from 11.6% (95% CI 10.9–12.3%) to 15.0% (95% CI 14.2–15.8%), p for 
trend < 0.0001 from 1992 to 2002. Among women, the PAF decreased nonsignificantly from 
22.0% (95% CI 20.9–23.2%) to 20.6% (95% CI 19.4–21.8%), p for trend 0.102 (Table 3 in IV). 
The trends in PAF were significantly different between the sexes (p < 0.001 for the year by 
sex interaction) (Fig. 8). 
 
Figure 7. Prevalence of diabetes (DM) among Finnish men and women and incidence of first 
acute coronary syndrome (ACS) in the population with diabetes during the years 1992–2002. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Population-attributable fraction (PAF) of the first acute coronary syndrome (ACS) 
due to diabetes during 1992–2002 in Finland. 
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6.5  Population-attributable fraction of ischaemic stroke (IV) 
 
As described above in chapter 6.4, the prevalence of DM increased substantially from 1992 
to 2002. Still, the annual incidence of first ischaemic stroke remained almost stable among 
men and decreased among women with DM (Fig. 9). The figure is based on further analysis of 
data in IV. 
 
Figure 9. Prevalence of diabetes (DM) among Finnish men and women and incidence of first 
ischaemic stroke event in the diabetic population during 1992–2002. 
 
 
 
Figure 10. Population-attributable fraction (PAF) of the first ischaemic stroke event due to 
diabetes from 1992 to 2002 in Finland. 
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The PAF of the first ischaemic stroke due to DM increased among men from 14.8% (95% CI 
13.6–16.0%) in 1992 to 16.0% (95% CI 14.7–17.3%) in 2002, p for trend 0.065, while the PAF 
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for women decreased from 21.5% (95% CI 20.1–22.9%) to 15.1% (95% CI 13.7–16.4%), p for 
trend < 0.001. Again, the trends in PAF were significantly different between the sexes (p < 
0.001 for the year by sex interaction) (Fig. 10).  
 
6.4  Population-attributable fraction of cardiovascular diseases (IV) 
 
The PAF of the first CVD event (either ACS or ischaemic stroke) due to DM showed an 
upward trend among men from 11.4% (95% CI 10.8–12.0%) to 13.8% (95% CI 13.2–14.5%), p 
for trend < 0.0001, and a downward trend among women from 20.1% (95% CI 19.2–21.0%) 
to 16.9% (95% CI 15.9–17.8%), p for trend 0.0005 (Table 3 in IV). These trends were 
significantly different between the sexes (p < 0.001 for the year by sex interaction) (Fig. 11). 
The change in PAF occurred mainly among men under 65 years, while in women the change 
occurred in all age groups. The PAF clearly increased with age in women, whereas in men the 
increase was modest (Table 4 in IV). 
 
Figure 11. Population-attributable fraction (PAF) of the first cardiovascular disease (CVD) 
event of either acute coronary syndrome or ischaemic stroke due to diabetes during 1992–
2002 in Finland. 
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7.  DISCUSSION 
7.1  Summary of the main findings 
 
This study confirmed that DM is a major risk factor for CVD. The PAF of the first ACS due to 
DM was 15% among men in 2002, with a significant increase since 1992. The PAF of the first 
ACS due to DM among women was 20.6% in 2002, with a nonsignificant decrease since 1992. 
The PAF of the first ischaemic stroke due to diabetes was 16.0% among men and 15.1% 
among women in 2002. These numbers were preceded by a very significant decrease among 
women and a nonsignificant increase among men since 1992. 
 
Almost 18% of T2DM patients had their first ACS during the study period and about 60% of 
ACS patients with DM died of CV causes within a year. Ischaemic stroke was also common 
among T2DM patients. Between 1.4% and 2.4% of patients with T2DM had their first 
ischaemic stroke each year. More than a third of them died of CV causes within a year of 
their stroke. 
 
Men with DM had higher prehospital, 28-day and total 1-year CF of the first ACS event in all 
age groups than women with DM. Both men and women with DM had higher 1-year CF of 
the first ACS event than their nondiabetic counterparts. The difference was biggest in the 
younger age group (35–74 years) of women, in whom the difference in 1-year fatality 
proportions was 17.3 percentage points. The CF decreased significantly in all groups studied 
and there was no difference in the pace of development between populations with and 
without DM from 1992 to 2002. 
 
Women with T2DM had somewhat higher CF of the first ischaemic stroke than men with 
T2DM. Patients with T2DM had a higher CV CF than nondiabetic patients both in the acute 
phase (1.1–1.3 times higher) and especially during the first year after the acute phase of 
stroke (1.4–2.2 times higher). The excess 28-day CF caused by T2DM was similar in both 
genders and in each age group, but the excess CF for the 28-day survivors was highest in the 
younger age group of women (HR 2.2, 95% CI 1.7–2.7).  
 
Diabetes remains a major risk for LEA, although the rate of major amputations has drastically 
decreased from 1988 to 2002 (Fig. 6). 
 
7.2  Study populations and methods 
7.2.1  Study populations 
 
This study was based on the nationwide Finnish registers of hospital discharges, 
reimbursements for the costs of medicines and causes of death. With the help of the 
personal ID the registers could be linked at the individual level. This setup enabled research 
that is unique in international comparison, because it allowed us to study the entire 
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population in Finland with long follow-up times. One can notice the benefits in comparing 
our results with those published in the international literature, in which most studies were 
based on very limited populations. 
 
DM diagnosis was mainly based on the use of hypoglycaemic medication, and to some extent 
on the information of the HDR. Information on the hypoglycaemic medication used came 
from the reimbursement registers of the Social Insurance Institute. These registers 
comprehensively covered patients using hypoglycaemic medication. The high level of 
coverage was due to the 100% special reimbursement of medicine costs if the disease was 
certified by a physician. The study data reached back to 1964 to identify these persons. Since 
1994, all prescribed purchases of hypoglycaemic medication have also been registered, and 
since hypoglycaemic medication is not available without a prescription, the register 
information is comprehensive. It must be pointed out that the reimbursement registers of 
the Social Insurance Institute do not include diabetic patients treated with diet only. 
Furthermore, the registers do not include permanently institutionalized patients who receive 
their medications from their institutes. Diseases of patients in the latter group are, however, 
included in the HDR. Some patients with DM who are treated with diet only may have been 
included in the HDR or the Causes-of-Death Register. It is, however, likely that this has 
occurred mainly in cases, in which DM has been a contributing cause for hospital treatment 
or death. Most patients from these two groups were thus not included in the diabetic 
population. 
 
Determining the type of DM involved some uncertainty, because we had to use indirect 
reasoning to do so. The type of DM was used only in the CF analyses, in which we were 
specifically interested in T2DM patients. The type was determined, based on age at the time 
of first diagnosis and the type of treatment given as described in the Methods section. 
 
The validity of the HDR and CVDR diagnoses in CVDs has been shown elsewhere (175,176). 
The FINSTROKE study has shown that towards the mid-1990s neuroimaging and/or autopsy 
have been performed on practically all patients with a symptomatic stroke (178).This has 
enabled reliable distinction between haemorrhagic and ischaemic stroke types (176), thus 
also focusing our interest in ischaemic strokes. We excluded all persons who had an ACS or 
stroke event before DM was mentioned for the first time in the registers and all those who 
were living abroad, according to the reimbursement register records.  
 
We determined the first-ever event of ACS or ischaemic stroke to be a 4-year event-free 
period. This 4-year period was kept the same for the later study years to avoid creating 
systematic bias. We estimated from our material that a 4-year period left us with about 8% 
falsely designated first ACS events and about 11–12% falsely designated first strokes. A 2-
year period would have given us about 15% falsely designated first ACS events, while a 7-
year period would still have left us with about 3% false first ACS events.  
 
For comparison, the same analyses were made for the nondiabetic persons in the National 
CVDR. This register is based on recorded linkage of the HDR, the Causes-of-Death Register 
and the National Drug Reimbursement Register. The CVDR covers all ACS and stroke events 
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in Finland that have led to hospitalization or death. The validity of the register has been 
described (175,176) and the summary tables as well as the methodological background are 
available in the Internet (185). The same ICD codes and the same definition for the first ACS 
and first ischaemic stroke event were used in this comparison material as in the diabetic 
material. Probability-based linkage of our DM register and the National CVDR was used to 
identify and remove persons with known DM from the National CVDR, because there was no 
personal ID available in the DM register. The linkage failed for 45 persons in the ACS analysis 
(0.1% of the patients with DM) and 41 persons in the stroke analysis (0.2% of patients with 
DM). These patients were excluded from the study population. 
 
As described above, the national registers allowed us to build a unique study population, and 
with careful definitions of various situations we believe we have been able to avoid many 
biases and have been able to form a basis for high-quality international research. A major 
limitation still remained: the study population did not include all patients who were treated 
for their DM with diet only, as described previously. Those presented with DM, but who were 
undiagnosed by the time of the study, were also not included. 
 
7.2.2  Methods 
 
The CF proportions of the first ACS and first ischaemic stroke were counted for persons 35–
94 years of age divided into two age groups. The ORs of prehospital deaths and the HRs of 0–
27- and 28–365-day fatalities were counted in four age groups. The division into four age 
groups proved to be useful, because it added information. Published articles have often 
included all diabetic persons in the analyses, including those younger and older, than we did. 
If we had also included all diabetic persons in the analysis, it would have helped in 
international comparisons. 
 
Dividing the CF analyses into the three periods (prehospital, 0–27-day and 28–364-day) gave 
valuable information on problems in the chain of care. An addition to this would be to also 
analyse in-hospital and posthospital periods separately. In-hospital analysis is, however, not 
unambiguous in register research. 
 
PAF analyses are valuable from the health political standpoint, because macroscale health 
problems can be detected and followed by this method. PAFs are recommended for use in 
assessing the potential impact of public health interventions (186). Interestingly, very few 
PAF analyses of DM have been reported: only a few on the PAF of CVD due to DM (168,169), 
some on CHD (170–172), one on stroke (187) and a few on LEAs (155,174). Unfortunately, 
the registers we used did not allow more widespread analysis of the PAFs of different risk 
factors in CVD events. 
 
In using the age scale 25–80 years, we may have excluded some of the additional burden DM 
causes in elderly people, especially in women. Again, one should consider also including 
elderly people for easier future international comparisons. 
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7.3  Case fatality of acute coronary syndromes 
 
Our study showed an RR of 1.33 for men and 1.48 for women with T2DM compared with the 
nondiabetic population in the younger age group of 35–74 years in the 1-year total CF. These 
figures are in line with studies from Australia in the late 1980s (141). The study in Finland 
that investigated the first ACS in patients 25–64 years of age showed 1-year HRs for 28-day 
survivors of 1.97 (95% CI 1.25–3.12) among men with DM and 4.17 (95% CI 2.05–8.51) 
among women with DM (142). The corresponding figures in our study for the age group of 
35–65 years in men and women with T2DM were 2.87 (95% CI 2.19–3.75) and 5.84 (95% CI 
3.70–9.23). Direct comparison of the figures is not possible, due to the difference in age 
groups and the fact that the previous study also included patients with T1DM. It seems, 
however, that very little positive development has been accomplished, although the authors 
of the 1988–1992 study recommended vigorous primary and secondary preventive measures 
(142). 
 
Our study showed a statistically significant difference between T2DM patients and 
nondiabetic patients in both genders and age groups in the total 28-day and 1-year CF after 
the first ACS. A study in the Netherlands was not able, after multivariate adjustment, to show 
any difference in 28-day CF, but they did show a difference in 1-year CF (143). A study in 
Germany that followed up 701 diabetic patients who had an ACS during 1998–2003 was 
likewise unable to find any difference between patients with DM and nondiabetic patients in 
28-day CF, but they did find an additional risk for 28-day survivors with DM in long-term 
follow-up (RR for men with DM 1.57 (95% CI 1.18–2.10) and women with DM 2.91 (95% CI 
1.82–4.65) (188). 
 
The literature shows that results of short-term care do not differ greatly, but long-term 
prognosis after the first ACS is worse for patients with DM. Our results showed that the 
prehospital fatality proportion is lower among T2DM patients than among nondiabetic 
persons, but at 28 days the CF among T2DM patients was already significantly higher. This is 
in line with the results from the Berlin Myocardial Infarction Registry, which collected 
information from 25 hospitals in Berlin between 1999 and 2002. The authors reported higher 
hospital mortality after an ACS event for women with DM than men, OR 2.28 (CI 95% 1.42–
3.68), for women with DM compared with nondiabetic women, OR 2.92 (95% CI 1.75–4.87) 
and no difference for men with DM compared with nondiabetic men (189). 
 
An interesting and important aspect is, whether any change has occurred in the CF after the 
first ACS among patients with DM compared with nondiabetic patients, especially when the 
decline has been shown in the general population (7,190–194). The follow-up of the NHANES 
study suggested that the trends have not been favourable among patients with DM (135). 
Between the periods 1971–1975 and 1982–1984, nondiabetic men showed a 36.4% decrease 
in age-adjusted heart disease mortality compared with a 13.1% decrease for men with DM. 
The decrease was 27% in nondiabetic women, but there was an increase of 23% in women 
with DM (135). A registry study from northern Sweden was not able to show a decrease in 
the 28-day CF among men or women with DM, but it did show a significant decrease among 
nondiabetic persons in the age group 35–64 years from 1989 to 2000 (144). The 1-year 
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mortality rate also decreased significantly among nondiabetic men and women, but not 
among men and women with DM. However, there was a downward trend among women 
with DM in both 28-day and 1-year CF (144).  
 
In our study we found that in all age groups the prehospital survival improved from 1992 to 
2002 and there was no difference in development between the T2DM population and the 
nondiabetic population, except for women with DM in the age group 85–94 years, whose 
prognosis improved more rapidly than in nondiabetic women of the same age. Again, the 
prognosis for 28-day survival and 1-year survival of 28-day survivors improved in all age 
groups of both genders and there was no difference in outcome between the T2DM and 
nondiabetic populations. In this respect, the results are somewhat better than those 
reported in other studies. The difference is probably again due to the fact that this study 
followed up the first ACS events, while many other studies followed any ACS event. 
 
The prehospital CF remained lower in T2DM patients than in nondiabetic patients in both 
genders and all age groups, except in the youngest group of 35–64 years. This is interesting, 
because it is often pointed out that in DM myocardial infarctions can occur with mild and 
confusing symptoms (195). DM is also an independent predictor of delay in ACS care (196). 
The development of ACS may be different in persons with DM and nondiabetic persons and 
this could explain the lower prehospital CF and higher long-term fatality. For instance, 
intravascular ultrasound has demonstrated that patients with DM tend to have a higher 
occurrence of vulnerable plaques than patients without DM (197). Poorer prognosis in 
persons with DM has resulted in special recommendations for improving the care of patients 
with DM in intensive care units (198). An influencing factor is also that many elderly patients 
with DM are already hospitalized for various reasons and therefore cannot die before 
hospitalization. 
 
A study from the Register of Information and Knowledge about Swedish Heart Intensive care 
Admissions showed that after adjusting for dissimilarities in baseline characteristics between 
ACS patients with and without DM, those with DM were significantly less likely to be treated 
with reperfusion therapy (OR 0.83), heparins (OR 0.88), statins (OR 0.88) or to be 
revascularized within 14 days from hospital discharge (OR 0.86) (199). Only the use of 
angiotensin-converting enzyme (ACE) inhibitors was more prevalent among patients with DM 
than in nondiabetic patients (OR 1.45), although all these treatments have equal benefit in 
patients with DM and nondiabetic patients (199). The conservative treatment schemes may 
be reflected in the Swedish prognosis figures: patients with DM had an adjusted relative 1-
year mortality risk after myocardial infarction of 1.44 (95% CI 1.36–1.52) in 1995–1998 and 
1.31 (95% CI 1.24–1.38) in 1999–2002 (200). Similar insufficient treatment was also reported 
from hospitals in Finland (201). Insufficient treatment of patients with DM has also been 
reported from Canada, where patients with DM were less likely to undergo coronary 
angiography (52.5% vs. 57%, p < 0.001) or revascularization (28.4% vs. 33.4%, p < 0.001). 
Compared with the group without DM, patients with DM had higher unadjusted rates of in-
hospital mortality (3.0% vs. 1.6%, p < 0.001) (202). 
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In our study, the fatality after hospital entry of the first ACS remained much higher in T2DM 
patients than in nondiabetic patients. This can be explained by the effect of DM itself, the 
differences in treatment in the hospital or primary and secondary prevention in outpatient 
care. Lipid-lowering therapy in T2DM decreases the incidence of CHD (203). CHD is also 
prevented by treatment for BP (88) and blood glucose (204). A study in Finland, monitoring 
secondary prevention in CHD showed that patients with DM used the same type of 
secondary prevention treatment as did nondiabetic patients: antithrombotic medication in 
about 90%, a beta-blocker in about 80% and a statin in about 60% (205). A recent study in 
Finland showed that beta-blocker use was high in the CHD populations with and without DM 
in 1997–2002, while ACE inhibitor and angiotensin II antagonist use increased and remained 
higher among patients with DM (206). More than half of men and women with DM used ACE 
inhibitors and one out of five used angiotensin II antagonists in 2002. Lipid-lowering 
medication use increased, especially among women with DM. Among men with DM the use 
of lipid-lowering medication remained lower than among nondiabetic men (206). Secondary 
prevention can also differ between genders. A study in Austria found that men were treated 
more favourably in all parameters measured and invasive treatments were used more often 
(207). A study in 12 countries in Europe and North America showed that 48.1% of those with 
DM were not at the total cholesterol target level compared with 58% of those without DM 
(208). This is in line with the Finnish results: 59% of T2DM persons had LDL-C ≤ 2.5 mmol/l 
and 27% had BP less than 135/85 mmHg (15). 
 
In referring the CF findings after the first ACS, development in outcomes among T2DM 
patients was favourable in Finland during the 1990s. Some positive development has 
occurred in treatment activity, but special effort is still needed in primary and secondary 
prevention of CV risk factors. 
 
7.4  Case fatality of ischaemic strokes 
 
We found that the 28-day CF was 1.1–1.3 times higher and the 1-year CF of 28-day survivors 
was 1.4–2.2 times higher in patients with T2DM than in nondiabetic patients after the first 
ischaemic stroke. The overall incidence of stroke has declined in Finland and the prognosis 
after stroke also improved during the period 1991–2002 (8), but in absolute numbers the 
annual incidence of first stroke among patients with DM remained stable in Finland in the 
1990s (29). DM affects about one fourth of stroke patients (149,150) and stroke is much 
more common in persons with DM than in nondiabetic persons, 1.5–8 times depending on 
age and gender, and more common in women (77–79,209). Research on prognosis after 
stroke in a person with DM has produced contrasting results in different countries. Results 
from Finland suggest a poorer prognosis for persons with DM; the 28-day CF was higher in 
patients with DM than in nondiabetic patients (20.0% vs. 16.9%, p = 0.020) (150). This 
register study considered all strokes, not only the first.  
 
We found a significant decrease in CF trends and no difference in trends of T2DM and 
nondiabetic patients. This was in line with the results that Booth et al. showed in their study; 
patients with DM experienced reductions in CF related to stroke similar to those without DM 
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(-17.1% vs. -16.6%, p = 0.9) from 1992 to 2000 (134). Over the same period, the number of 
DM cases increased from 405 471 to 670 602. Thus, while CVD rates fell, the number of 
events occurring in this population increased (134). A study in Veterans Administration 
hospitals in the U.S. followed up 13 925 patients with DM after an ischaemic stroke between 
1990 and 1997. The 60-day and 1-year fatality proportions were similar in patients with and 
without DM (2.9% vs. 2.7%, p = ns and 12.6% vs. 13.1%, p = ns, respectively), but the RR for 
fatal outcome among patients with DM was 1.15 (95% CI 1.11–1.19, p < 0.001) after 
controlling for covariates (149). A study from Austria showed similar CF among stroke 
patients with and without DM (210). A study in Denmark showed that only age was 
associated with a poor early prognosis after stroke, but DM was associated with poorer late 
prognosis: OR at 90 days 1.35 and at 1 year 1.33 (211). 
 
A literature search suggests that there is a difference in survival after ischaemic stroke that 
favours the nondiabetic population, especially over the long term. DM is considered to be 
the strongest predictor of fatal outcome within 5 years after the stroke (212). This again 
brings up the question about time trends when the results of stroke patients with and 
without DM are compared. Are the patients with DM catching up on the additional risk gap 
they have? The literature furnishes no answers to this question. Our results suggest that the 
prognosis of stroke in patients with T2DM has improved as it has in nondiabetic patients in 
Finland, although the gap between patients with DM and nondiabetic patients has remained. 
 
Again the question is raised: does T2DM as such pose the extra burden or are there other 
factors that could be tackled? The INTERSTROKE study in 22 countries showed that the 
combined PAR of following risk factors may be responsible for 90% of ischaemic stroke 
events: hypertension (OR 2.64), current smoking (OR 2.09), waist-to-hip ratio (OR 1.65), diet 
risk score (OR 1.35), regular physical activity (OR 0.69), DM (OR 1.36), alcohol intake (OR 
1.51, for more than 30 drinks per month or binge drinking), psychosocial stress (OR 1.30), 
depression (OR 1.35), cardiac causes (OR 2.38) and ratio of apolipoproteins B to A1 (OR 1.89) 
(148). It should be noted, however, that the INTERSTROKE study used a cross-sectional case-
control design, which limits these inferences. Nevertheless, modifiable risk factors count 
greatly and should be better tackled. For instance, only 27% of T2DM patients in Finland 
reach the BP target of less than 135/85 mmHg (15) and 49.7% are obese (BMI > 30 kg/m²) 
(213). A study in the U.S. showed that stroke survivors have several risk factors that 
predispose them to further CV events: 18% of those with hypertension did not receive 
medication and 55% of those that were treated did not reach the target level of < 140 
mmHg, but were an average of 20 mmHg above the target level (214). 
 
Women with T2DM had higher CF proportions in both age groups and time periods 
considered (0–27 days and 28–364 days after the stroke) than men with T2DM in our study. 
This could have resulted from the predisposing factors for stroke (hypertension, atrial 
fibrillation, congestive heart failure and valvular heart disease), which are more common in 
women (215), or that men have more lacunar infarctions, which have more favourable 
prognoses, than women (216). It is also possible that women are treated less actively after 
an ischaemic stroke, as has been the case for female coronary patients in Finland (205).  
 
42 
 
Our results were in line with those from northern Sweden. Rautio et al. found that there was 
a significant decrease in the incidence of first strokes among both persons with DM and 
nondiabetic persons in northern Sweden (79). The CF of the first stroke also decreased 
significantly in all other groups, except younger women with DM (79). In our study, even this 
group made significant progress.  
 
In conclusion, we were able to show significant downward trends in the CV 28-day CF and 
28–364-day CF of 28-day survivors after the first ischaemic stroke in persons with T2DM. The 
trends were similar to those in nondiabetic persons and better than in many other reports 
from other countries.  
 
7.5  Lower-extremity amputations 
 
People with DM have a 5–20-fold higher risk for amputation (155,217,218). Thus, the CV risk 
caused by DM seems to be highest in the lower extremities. The age-adjusted amputation 
incidence in the total population of southern Finland fell by 30% from 1990 to 2000 (9). 
Again, we wanted to know whether the positive trend in the general population also applies 
to persons with DM. 
 
Reports from other countries have not shown very promising results in the population with 
DM. A study in Australia was not able to show any change in major amputation rate from the 
period 1998–1999 to 2007–2008 (219). A study in England likewise found no change in DM-
related amputation rate from 2004 to 2008 (154). Both of these studies analysed all 
amputations, which leaves several uncertainties in interpretation of the results, because 
several LEAs can be done in the same person.  
 
Our study showed that although there is a wide variation in different areas of Finland, the 
crude rate of major LEAs shows a strong downward trend. This was in line with a study from 
Scotland which showed that from 2000 to 2006 the incidence of major amputations fell from 
5.1 (95% CI 3.8–6.4) to 2.9 (95% CI 1.9–3.8) per 1000 patients with diabetes (P < 0.05) (220) 
and from Sweden, where the incidence of major amputations in persons with DM decreased 
from 16 (95% CI 11–22) to 6.8 (95% CI 6.1–7.5) per 100 000 inhabitants between the first and 
last 4-year period during 1982–2001 (161). Similar results have been reported from the 
Veterans Health Administration in the U.S.: age- and sex-standardized first LEA rates 
decreased by 34% (7.08 per 1000 patients with DM in 2000 to 4.65 per 1000 patients with 
DM in 2005) (221). The rate of major amputations decreased 36% during the same period 
(221). We previously showed that the absolute number of amputations among persons with 
DM in Finland slowly increased from 998 in 1988 to 1224 in 2002 (29). Thus, despite the 
positive results, we were left with uncertainty. Later we analysed the development in the RR 
of first major amputations among persons with DM compared with nondiabetic persons 
(156). The age-standardized RR among men with DM fell from 11.7 (95% CI 10.9–12.4) in 
1997–2000 to 7.0 (95% CI 6.5–7.4) in 2004–2007. The change in age-standardized RR for 
women with DM fell from 8.8 (95% CI 8.3–9.3) to 4.5 (95% CI 4.2–4.8) (Table 4) (156).  
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Table 4. Relative risk (RR) of the first major amputation among persons with diabetes (men 
and women separately by age groups) vs. nondiabetic persons during 1997–2000 and 2004–
2007 (with permission of Diabetes Care) (156). 
 1997–2000 
RR (95% CI) 
2004–2007 
RR (95% CI) 
Men by age groups (years)   
   30–49 55.5 (42.1–71.9) 35.9 (26.1–48.2) 
   50–64 22.9 (19.9–26.2) 16.2 (14.2–18.3) 
   65–74 13.5 (12.1–15.0) 7.4 (6.5–8.3) 
   75+ 7.3 (6.6–8.2) 4.5 (4.0–5.0) 
   All 11.7 (10.9–12.4) 7.0 (6.5–7.4) 
Women by age groups (years)   
   30–49 81.1 (54.7–115.8) 55.0 (34.9–82.5) 
   50–64 29.3 (22.9–37.1) 19.8 (15.5–25.0) 
   65–74 18.1 (15.9–20.6) 7.1 (5.8–8.5) 
   75+ 6.9 (6.4–7.4) 3.7 (3.4–4.0) 
   All 8.8 (8.3–9.3) 4.5 (4.2–4.8) 
 
One could expect that smoking increases the amputation rate in a diabetic population in the 
same manner as it does in the general population (222,223). A study in Japan showed that 
the OR for amputation among heavy smokers was 2.07 (95% CI 1.11–3.85) in a multivariate 
analysis among T1DM patients (224). Due to the hazardous effect of smoking on the 
development of PAD, some of the differences in amputation rates can be explained by the 
prevalence of smoking. In a study in Finland 12.7% of T2DM patients and 21.1% of T1DM 
patients were daily smokers in 2008 (213).  
 
A study in the U.S. showed a 2.10 (95% CI 1.17–3.77) RR of LEA for persons with DM, who 
had the disease before the age of 30 and 1.19 (95% CI 0.57–2.48) for those who contracted 
the disease after the age of 30 (225). Chronic kidney disease increases the risk for PAD (226). 
 
Diabetic neuropathy is a strong predictor of foot problems. It was estimated that 50% of 
diabetic foot ulcerations and LEAs can be prevented by identifying the foot at risk and 
implementing preventive strategies (227). Neuropathy causes the lack of protective 
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sensation, which allows ulceration in areas of high pressure. Autonomic neuropathy causes 
dryness of the skin by decreased sweating and therefore vulnerability of the skin to ulcers. 
Diabetic neuropathy is a result of microangiopathy, in which again hyperglycaemia plays a 
major role. In 1993 the average HbA1c was 8.8% among patients with DM (228). This partly 
explains the high incidence of amputations. Much remains to be accomplished in developing 
the total chain of services to prevent diabetic foot problems and amputations. 
 
7.6  Population-attributable fraction of acute coronary syndrome  
 
Our study showed no change in the PAF of ACS due to DM for women, while we found a 
significant increase in the PAF for men. The significant change in the male population 
occurred in the younger age groups of 25–54 years and 55–64 years. Interestingly, at the 
same time women showed a downward trend that was nonsignificant. The trends in PAF 
were significantly different between the sexes (p < 0.001 for the year by sex interaction), 
although the PAF remained higher level among women (20.6% vs. 15.0%). The diverging 
development for men and women could have been due to the greater increase in obesity 
among men than among women (229), which has increased the number of cases more in 
men than in women among people with DM, although recent studies showed that women 
are now gaining weight at a faster pace (230). Pajunen et al. compared five cohorts from 
different time periods; the annual increase in body weight among men between 25 and 54 
years old remained stable in the range of 0.27–0.47 kg per year over the decades, whereas 
women belonging to the most recent cohorts (during the 1990s) gained weight in amounts of 
0.53–0.63 kg per year, which is more than double the oldest cohort's weight gain of 0.24 kg 
per year (230). Another, even stronger, explanation for the gender difference could be that 
we analysed the age group 25–80 years. This could have affected the results, because 
women tend to have their first ACS event about 10 years later than men (231,232).  
 
The INTERHEART Study showed a PAF of 9.9% for ACS due to DM in 52 countries (131). This is 
less than our results (15.0% for men and 20.9% for women), but it should be remembered 
that our study focused on the first event. The difference also reflects the high prevalence of 
DM in Finland. 
  
7.7  Population-attributable fraction of ischaemic stroke 
 
The development in PAF of ischaemic stroke due to DM followed the same pattern as the 
PAF of ACS. DM still had a greater influence on PAF among women than among men, but 
while DM in women is becoming less influential on the PAF of ischaemic stroke, the 
contrasting situation is occurring among men. This may be due to the increasingly better 
treatment of women with DM or simply to their compliance with the recommended 
treatments. The INTERSTROKE Study, which is a cross-sectional case-control study, reported 
that the PAF of ischaemic stroke due to DM in 22 countries was 5.0% (99% CI 2.6–9.5%) 
(148). This study, as ours, focused on the first stroke, but the PAF was much smaller than in 
our study, in which the last study year showed a PAF of 15–16%. One explanation for the 
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high figures in our study may be high BP, in which treatment goals are seldom reached. A 
study from Finnish general practice showed that only one fourth of hypertensive patients 
reached a BP level of 140/85 mmHg (233). It was estimated that 75% of CVD is explained by 
high BP in patients with DM (90). The INTERSTROKE study estimated that the PAF due to 
history of BP was 34.6% (99% CI 30.4–39.1%) (148). Concomitant hypertension in DM 
doubles the risk for stroke (132). 
 
7.8  Population-attributable fraction of cardiovascular diseases 
 
Very few results are available from the last decade on the PAF of CVD due to DM. Our 
finding, showing an increasing PAF of the first CVD event due to DM for men, was in line with 
the report from the Framingham Heart Study (168). In the Framingham study, the 
researchers followed a narrower age group of people (45–64 years) than we did. They 
examined all CVD events, not only the first ones, and also included TIA, claudication and 
heart failure, while our material covered the first ACS and stroke events. In the Framingham 
study, the PAF of CVD was 5.4% (95% CI 3.8–6.9%) during the years 1952–1974 and 8.7% 
(95% CI 5.9–11.4%) during the years 1975–1998. Most of the change occurred among men as 
it did in our material in the same age group. 
 
The PAF figures of the later period of the Framingham study are somewhat lower than those 
in our study population, probably due to the younger age group. The Finnish PAF of CVD due 
to DM is closer to the figures from Brazil, where the PAF due to DM was 10.1% for CVD 
mortality and 13.1% for total CVD (234). This study was based on a population cohort of 1019 
persons. 
 
PAF analyses gave interesting information on the burden of DM on CVD first events in 
Finland. The threat of a DM `tsunami´ overloading hospitals treating CVDs seems to some 
extent exaggerated. The positive development among women, in whom the PAF of CVD is 
decreasing, seems promising. 
 
7.9  Strengths and limitations of the study 
 
The main strength of our study was that we were able to analyse the development in 
incidence of macrovascular complications of DM in the entire population of Finland. This was 
due to the comprehensive register data in the Finnish national registers of hospital 
treatment, causes of death and medication used. The national registers also enabled us to 
follow the development for long periods of time. Comprehensive registers of total 
populations include large numbers of observations with strong statistical power, which also 
makes it possible to observe weak signals. The existing National CVDR made it possible to 
make comparisons with the nondiabetic population, which also reinforced our results.  
 
While the strengths of this study came from the comprehensive register materials, the 
registers also constituted the limitations of the study. The diagnosis of DM was based on the 
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register information. In most cases the diagnosis was based on the Reimbursement Register 
or Sales of Medicines Register of the National Social Security Institute, because the other 
registers (HDR and Causes-of-Death Register) seldom included the diagnosis of DM for those 
that were treated with diet only. The group of patients with DM who are treated with diet 
only is continually becoming smaller with modern treatment regimens. Thus, the estimated 
increase in the prevalence of DM based on the registers was upwardly biased for two 
reasons. The first was the more active use of hypoglycaemic medications towards the end of 
the study period. The second reason is the changed definition of DM (12). Nevertheless, 
most of the increase is likely to be real and due to increasing obesity. 
 
Another limitation is that the registers used are primarily designed for administrative 
purposes and the diagnoses in them have not been standardized in a scientific manner. 
There are, however, several published validation studies on CV diagnoses in these registers 
and their validity has generally been favourable (175,176). As usual in this type of study, we 
analysed clinically symptomatic ACS and stroke events only. Identifying clinically silent 
coronary and stroke events is not possible from these data sources. 
 
7.10  Clinical implications 
 
The study results show that persons with DM have benefited from the development of 
medicine and new therapies in the same way as the nondiabetic population. The rate of 
change was about the same in both groups, but the difference in outcome remained the 
same for most of the indicators used.  
 
Many studies have shown that macrovascular complications can often be prevented if the 
risk factors are aggressively treated. Unfortunately, however, many times the risks are less 
well treated in the population with DM than in the nondiabetic population. Early, aggressive 
treatment should be the goal in DM treatment. 
 
We found that often the prognosis of a patient with DM is similar to a nondiabetic patient in 
the first phase of hospital treatment, but later after the acute event the survival decreases 
more rapidly in the population with DM. Thus, secondary prevention should be emphasized 
after a macrovascular event in a person with DM. With active primary and secondary 
prevention, and treating the total risk load of a person with DM, the risk of CVD events could 
be lowered drastically. 
 
7.11  Future research needs 
 
Continuous feedback with healthcare producers on acute CV events in the population with 
DM would be helpful. In principle, this could occur by including information about DM in the 
National CVDR or, alternatively, enabling annual record linkage between the DM register and 
CVDR. Since DM is increasing rapidly, the incidences should be counted for the total 
population. 
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The CF of the first ACS, stroke or LEA event should be constantly followed up by comparing 
the results in the populations with and without DM. This would give a good basis for quality 
evaluations of treatment regimens. Regional analysis, e.g. by university hospital district or 
hospital district, would give even better grounds for local decision making. 
 
Following up the PAF of CVD events due to DM at intervals of few years is also important. 
This information forms a strong basis for political decision making in planning resource 
delivery in society and healthcare. In Finland, the PAF of amputations due to DM should be 
counted especially, because we did not cover it during our study. 
 
Future studies of all age groups should be included. This would make international 
comparison easier. The differences between genders should be thoroughly examined. Future 
studies could also follow up the effect of different medications. The registers we used would 
allow us, with certain limitations, to study the effects of various hypoglycaemic, BP and lipid-
lowering medications. This may help to find answers for why patients with DM progress 
more poorly than nondiabetic patients. Future registers of ambulatory care will also allow 
comparison of the influence of risk factors, such as smoking, or various laboratory test 
results, on the outcomes. 
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8.  CONCLUSIONS 
 
DM is still a major risk factor for CVD in Finland. The PAF of first CVD events due to DM was 
about 15% in 2002, somewhat less for men (13.8%), but increasing since 1992, and 
somewhat more for women (16.9%), but decreasing. The PAF of the first ACS increased 
significantly since 1992 among men and decreased nonsignificantly among women. The PAF 
of the first ischaemic stroke showed a nonsignificant increase among men since 1992 and a 
very significant decrease among women. There is no clear explanation for the differences in 
development among men and women. These should be studied further. 
 
Almost 18% of T2DM patients had their first ACS during the study period and about 60% of 
ACS patients with T2DM died within a year in CVDs. Ischaemic stroke was also common 
among patients with T2DM. Between 1.4% and 2.4% of patients with T2DM had their first 
ischaemic stroke each year. More than a third of them died of CV causes within a year of 
their stroke. The total 1-year CF after the first ACS or ischaemic stroke is very high and special 
attention should be focused on improving the situation. Secondary prevention after the 
hospitalization period should receive an especially high priority. 
 
Men with DM had higher prehospital, 28-day and total 1-year CFs of the first ACS event in all 
age groups than women with DM. Both men and women had higher 1-year CFs of the first 
ACS event than their nondiabetic counterparts. The difference was biggest in the younger 
age group (35–74 years) of women, in whom the 1- year fatality proportion difference was 
17.3 percentage points. The CFs decreased significantly in all groups studied and there was 
no difference in the pace of development between populations with and without DM from 
1992 to 2002. 
 
Women with T2DM had somewhat higher CF of the first ischaemic stroke than men with 
T2DM. Patients with T2DM had a higher CV CF than nondiabetic patients both in the acute 
phase (1.1–1.3 times higher) and especially during the first year after the acute phase of 
stroke (1.4–2.2 times higher). The excess 28-day CF caused by T2DM was similar in both 
genders and in each age group, but the excess CF for the 28-day survivors was highest in the 
younger age group of women (HR 2.2, 95% CI 1.7–2.7). Persons with DM should have strict 
goals in the treatment of all CV risks they have. 
 
DM remains a major risk for LEA, although the rate of major amputations has drastically 
decreased from 1988 to 2002. 
 
Patients with DM have benefited from the prevention of CVDs approximately to the same 
extent as their nondiabetic counterparts. Yet, their risk of developing CVD remains higher 
and the prognosis after a CV event is poorer, particularly in long-term prognosis after the 
acute stage of the event. In addition to the primary prevention, more attention should be 
focused on the secondary prevention of CV events among patients with DM. 
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